Interferon News and Research

RSS

Vitamin D puts a brake on activated macrophages - newly discovered mechanism keeps inflammation under control

When macrophages, the first line defender cells of the immune system become activated, they produce an inhibitor, which acts back on them to suppress their activity.

29 Aug 2005

Interferon selectively kills colon cancer cells when combined with irinotecan chemotherapy agent

Johns Hopkins Kimmel Cancer Center scientists have found that interferon, used for 30 years to treat blood cancers, multiple sclerosis and hepatitis, selectively kills colon cancer cells when combined with another standard chemotherapy agent.

16 Aug 2005

Pseudomonas aeruginosa has broken the immune system's code

The human opportunistic pathogen, Pseudomonas aeruginosa, has broken the immune system's code, report researchers from the University of Chicago, enabling the bacteria to recognize when its host is most vulnerable and to launch an attack before the weakened host can muster its defenses.

1 Aug 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

Studies compare hepatitis B drugs

According to a new study Roche's brand of interferon can help control the potentially deadly liver infection, hepatitis B, better than a competitor's drug.

30 Jun 2005

New UK Guidance to be issued on Hepatitis C as 'silent epidemic'

Leading medical experts from throughout the UK will be gathering in Edinburgh today and tomorrow (21-22 April 2004) to arrive at a consensus on how best to treat and manage the 'silent epidemic' of hepatitis C - a virus which is estimated to be carried by over 400,000 people in the UK and which continues to spread globally, as the majority of carriers do not realise they have been infected.

21 Jun 2005

Researchers discover how hepatic-C virus evades immune system in acute and chronic infections

Researchers at Johns Hopkins have uncovered how a majority of the genetic changes in the hepatic-C virus, the most common cause of liver disease, allow it to evade the body's immune system during infection.

10 Jun 2005

Helix opens additional sites for its Topical Interferon Alpha-2b Phase II clinical study

Helix BioPharma announced today the opening of two additional German sites for the Phase II clinical trial of its Topical Interferon Alpha-2b product at the Charité Berlin, one of the largest university hospitals in Europe.

2 Jun 2005

Study shows using expanded critera donors is safe

Patients who had received livers from hepatitis B virus core antibody (HBcAb) positive (indicates prior exposure to hepatitis B) and/or hepatitis C virus (HCV) positive donors had similar graft and patient survival compared to patients who received HBcAb negative or HCV negative livers, according to a study by the University of Pittsburgh's Thomas E. Starzl Transplantation Institute.

25 May 2005

New hope for people with hepatitis C

University of New South Wales (UNSW) researchers are running two new studies on hepatitis C, which could revolutionise treatment for the virus.

22 May 2005

Intralesional immunotherapy for common warts is effective and safe

Injection of skin test antigens (preparations used in skin tests for immunity) into warts appears to stimulate the immune system and successfully treat the injected wart and also helps to treat distant non-injected warts, according to a study in the May issue of Archives of Dermatology.

16 May 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Milk thistle not proven effective in lowering mortality in alcoholic or hepatitis B or C liver disease

While some studies found that liver-related mortality may be significantly reduced in patients treated with milk thistle, these findings were not duplicated in the higher quality clinical trials.

2 May 2005

Small number of genes can predict response to chronic hepatitis C therapy

For the first time, physicians at University Health Network and University of Toronto have identified a small subset of genes that can predict whether a patient with chronic Hepatitis C will be able to respond to current treatments.

2 May 2005

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

Dose-limiting anemia can be a prominent adverse event of therapy with pegylated interferon and ribavirin. This dose-ranging study examined whether viramidine, a liver-targeting prodrug of ribavirin, may be a safer alternative when used in combination with pegylated interferon alfa-2a/ PEG-IFN (Pegasys).

23 Apr 2005

Asthmatics naturally deficient in antiviral immunity

Asthmatics produce lower levels of a type of immune cell protein needed to fight off infection from colds and other viruses, scientists have discovered.

6 Apr 2005

New weapon for asthmatics to combat winter asthma attacks

A British team from the University of Southampton, led by the world-acknowledged asthma experts, Professor Stephen Holgate and Professor Donna Davies, has identified a therapy used to treat multiple sclerosis (MS) as a potential novel treatment to reduce asthma attacks caused by the common cold virus.

23 Mar 2005

Why respiratory viral infections are often more severe in people with asthma

Lung cells from asthma sufferers fail to invoke critical anti-viral defenses when infected with the common cold virus, according to a study in the March 21 issue of The Journal of Experimental Medicine. These results could help explain why respiratory viral infections are often more severe in people with asthma and how infection can trigger asthma attacks.

21 Mar 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Medical House signs 10 year license and supply agreement with BioPartners GmbH

The Medical House, orthopaedic devices and drug delivery company and BioPartners GmbH the global biopharmaceuticals company are pleased to announce a 10 year agreement for license and supply of The Medical House's GH1 reusable, spring-powered, needle-free delivery system for the delivery of BioPartners’ human growth hormone product, Valtropin.

22 Feb 2005